Gobeil, Fernand Jr

Professeur, Faculté de médecine et des sciences de la santé
FMSS Département de pharmacologie-physiologie

Coordonnées

Courriel


819-821-8000, poste 72378

Diplômes

(2002) Postdoctorat (Postdoctorat en pharmacologie). Université de Montréal.

(1999) Doctorat (Doctorat en pharmacologie). Université de Sherbrooke.

(1994) Maîtrise avec mémoire (Maîtrise en pharmacologie - Maîtrise). Université de Sherbrooke.

(1992) Baccalauréat (Baccalauréat en biochimie). Université du Québec à Montréal.

Présentation

Sujets de recherche

Maladies cardiovasculaires, Signalisation cellulaire et cancer.

Disciplines de recherche

Oncologie, Pharmacologie.

Mots-clés

biologie moléculaire, biologie vasculaire, cancer, drug design, GPCR, kinines, maladie cardiovasculaire, modèles animaux, peptides, pharmacologie.

Intérêts de recherche

Expression, localisation et corrélation fonctionnelle des récepteurs couplés à des proteines G (GPCRs) en physiologie et physiopathologie

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français

Prix et distinctions

  • (2020) Research & Creativity Award Winner (Faculty of medicine and health sciences). Co-winner: Dr JL Ardilouze MD. Université de Sherbrooke. (Prix).
  • (2015) Senior scholarship. Fonds de recherche du Québec - Santé (FRQS). (Prix).
  • (2011) Junior 2 Scholarship. Fonds de recherche du Québec - Santé (FRQS). (Prix).
  • (2007) Junior 1 Scholarship. Fonds de recherche du Québec - Santé (FRQS). (Prix).
  • (2007) Young Investigator Award. Kinin 2007 International Conference. (Distinction).
  • (2002) Fellowship (post-doctorate). Instituts de recherche en santé du Canada. (Prix).
  • (2002) Postdoctoral Scientist Award (ASPET). FASEB meeting. (Distinction).
  • (1998) Studentship (Ph.D.). Fondation des Maladies du Coeur. (Prix).
  • (1997) Academic Dean's List (Ph.D.). Université de Sherbrooke. (Distinction).
  • (1997) Studentship (Ph.D). Conseil de recherches en sciences naturelles et en génie (CRSNG). (Prix).
  • (1994) Finalist for the Governor General's Academic Medal. Université de Sherbrooke (M.Sc.). (Distinction).
  • Canada Foundation for Innovation (CFI) New Opportunities Award. CFI. (Distinction).

Financement

Subvention. (Obtenu). Cochercheur. Venous anti-thrombotic properties of the chymase inhibitor fulacimstat. Institute of Pharmacology, Univ. Sherbrooke. IPS-Innovation competition 2019. 30000 $ (2019-2021).

Subvention. (Obtenu). Chercheur principal. Improving CNS delivery of therapeutic biologics with novel kinin functionalized, TRIOZAN-based nanoparticles. Canadian Glycomics Network / PSO - MEI-Québec. Strategic Initiatives. 260000 $ (2019-2021).

Subvention. (Obtenu). Chercheur principal. Preclinical validation of humanized chicken recombinant antibodies targeting GPCRs overexpressed in cancers. Consortium québécois sur la découverte du médicament (CQDM). SynergiQc. 1088985 $ (2018-2021).

Subvention. (Obtenu). Cochercheur. Un inhibiteur de la chymase corrige la thrombose veineuse profonde sans induire de saignement. Axe-Thème/ CEUS DOCC. Axe-Thème/ CEUS DOCC competition 2019. 10000 $ (2019-2020).

Subvention. (Obtenu). Candidat principal. A novel class of vasoactive nanodevices to enhance drug delivery to the brain. Institute of Pharmacology, Univ. Sherbrooke. Innovation Project Competition 2017. 40000 $ (2017-2019).

Subvention. (Obtenu). Cochercheur. Regulation of G protein-coupled receptors by their cognate alternative proteins. (2014-2019).

Contrat. (Obtenu). Chercheur principal. Development of therapeutic antibodies against cancer. Government of Québec - Ministry of Economy, Science and Innovation. Passeport Innovation. 71816 $ (2017-2018).

Subvention. (Obtenu). Cochercheur. Camouflage of the war between CSII catheter and subcutaneous adipose tissue. Juvenile Diabetes Research Foundation (JDRF). JDRF-type 1 diabetes research program. 222827 $ (2016-2018).

Subvention. (Obtenu). Candidat principal. Improving CNS delivery of oncotherapeutics with novel kinin-based BBB permeabilizers. Drug Research Quebec Network (RQRM). Identification and Validation of Therapeutical Targets. 50000 $ (2016-2018).

Subvention. (Obtenu). Cochercheur. Nouveaux outils moléculaires pour la détection des récepteurs B1 des kinines par TEP.. (2014-2017).

Subvention. (Obtenu). Cochercheur. Visualisation of important steps in the formation of brain metastases. (2012-2017).

Subvention. (Obtenu). Chercheur principal. Inducible kinin B1 receptors as prostate cancer theranostic targets. (2014-2016).

Subvention. (Obtenu). Chercheur principal. Toxicological profile and pharmacokinetics of a peptidomimetic agonist of the kinin B1 receptor. (2013-2015).

Subvention. (Obtenu). Chercheur principal. Design and characterization of novel theranostic probes for brain cancer. (2014-2015).

Subvention. (Obtenu). Chercheur principal. Novel kinin receptor agonists to potentiate CNS drug delivery for the therapy of glioma. Centre for Drug Research and Development (CDRD). 50000 $ (2014-2015).

Publications

Articles de revue

  • Nunes MA, Toricelli M, Schöwe NM, Malerba HN, Dong-Creste KE, Farah DMAT, De Angelis K, Irigoyen MC, Gobeil F, Viel TA, Buck HS. (2020). Kinin B2 receptor activation prevents the evolution of Alzheimer’s disease pathological characteristics in a transgenic mouse model. Pharmaceuticals, 13(288), 1-16. (Article publié).
  • Sikpa D, Whittingstall L, Savard M, Lebel R, Côté J, McManus S, Chemtob S, Fortin D, Lepage M, *Gobeil F. (2020). Pharmacological modulation of blood-brain barrier permeability by kinin analogs in normal and pathologic conditions. Pharmaceuticals, 13(279), 1-21. (Article publié).
  • Gagnon M, Savard M, Jacques JF, Bkaily G, Geha S, Roucou X, *Gobeil F. (2020). Potentiation of B2 receptor signaling by AltB2R, a newly identified alternative protein encoded in the human bradykinin B2 receptor gene. J Biol Chem, N/A, N/A. (Révision demandée).
  • Savard M*, Dubuc C*, Bovenzi V*, Lessard A, Côté J*, Neugebauer W, Geha S, Chemtob S, Gobeil jr F. (2019). Anti-tumor activity of cell-penetrant kinin B1 receptor antagonists in human triple-negative breast cancer cells. Journal of Cellular Physiology, 234(3), 2851-2865. (Article publié).
  • Jafari L, Savard M, Gobeil F, Langelier E. (2019). Characterization of moderate tendinopathy in ex vivo stress-deprived rat tail tendons. Biomed Eng, 18(1), 1-16. (Article publié).
  • Jafari L, Hassanisaber H, Savard M, Gobeil F, Langelier E. (2019). Efficacy of combining PRP and MMP inhibitors in treating moderately damaged tendons ex vivo. J Orthop Res., DOI 10.1002/jor.2431(May 24), 1838-1847. (Article publié).
  • Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. Br J Pharmacol, 176(Suppl 1), S21-S141. (Article publié).
  • Bonato L, Taleb N, Gingras V, Messier V, Gobeil F, Ménard J, Ardilouze JL, Rabasa-Lhoret R. (2018). Duration of catheter use in patients with diabetes using continuous subcutaneous insulin infusion: A review. Diabetes Technology & Therapeutics, 20(7), 506-515. (Article publié).
  • Houde M, Schwertani A, Desbiens L, Touil H, Sarrhini O, Lecomte R, Lepage M, Gagnon H, Takai S, Pejler G, Jacques D, Gobeil F, Day R, D'orléans-Juste P. (2018). Mouse mast cell protease 4 deletion protects heart function and survival after permanent myocardial infarction. Front. Pharmacol., 9, 1-15. (Article publié).
  • Dubuc C*, Savard M*, Bovenzi V*, Lessard A, Fortier A*, Côté J*, Neugebauer W, Rizzolio F, Geha S, Giordano A, Chemtob S, Gobeil F. (2018). Targeting intracellular B2 receptors using novel cell-penetrating antagonists to arrest growth and induce apoptosis in human triple-negative breast cancer. Oncotarget, 9(11), 9885-9906. (Article publié).
  • Regoli D & Gobeil F. (2017). Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system. Can J Physiol Pharmacol, 95(10), 1117-1124. (Article publié).
  • Ardilouze JL, Ménard J, Gobeil F, Gagnon-Auger M*, Houde G, Pesant MH, Rabasa-Lhoret R, Baillargeon JP. (2016). CSII: Longer Catheter Usage Time, a Reasonable Goal. J Diabetes Sci Technol, 10(4), 989-990. (Article publié).
  • Dong-Creste KE, Baraldi-Tornisielo B, Caetano AL, Gobeil F, Montor WR, Viel TA, Buck HS. (2016). Kinin B1 receptor mediates memory impairment in the rat hippocampus. Biological Chemistry, 397(4), 353-364. (Article publié).
  • Regoli D & Gobeil F. (2016). Kinins and peptide receptors. Biological Chemistry, 397(4), 1207-304. (Article publié).
  • Savard M*, Côté J*, Tremblay L, Neugebauer W, Regoli D, Gariépy S, Hébert N, *Gobeil jr F. (2016). Safety and pharmacokinetics of a kinin B1 receptor peptide agonist produced with different counter-ions. Biological Chemistry, 397(4), 365-372. (Article publié).
  • Regoli D, Gobeil Jr F. (2015). Critical insights into the beneficial and protective actions of the kallikrein-kinin system. Vascular Pharmacology, 64, 1-10. (Article publié).
  • Boshle V, Gobeil F jr, Rivera JC, Ribeiro-da-Silva A, Chemtob S. (2015). High resolution imaging and function of nuclear G-protein coupled receptors (GPCRs). Methods Molecular Biology, 1234, 81-97. (Article publié).
  • Desposito D, Potier L, Chollet C, Gobeil Jr F, Roussel R, Alhenc-Gelas F, Bouby N, Waeckel L. (2015). Selective kinin receptor agonists restore postischemic neovascularization in diabetic mice. J Pharmacol Exp Ther, 352, 218-226. (Article publié).
  • Gobeil F Jr, Sirois P, Regoli D. (2014). Preclinical pharmacology, metabolic stability, pharmacokinetics and toxicology of the peptidic kinin B1 receptor antagonist R-954. Peptides, 52, 82-89.
  • Joyal JS*, Nim S*, Zhu T*, Sitaras N, Rivera JC, Shao Z, Sapieha P, Hamel D, Sanchez M, Zaniolo K, St-Louis M, Ouellette J, Montoya-Zavala M, Zabeida A, Picard E, Hardy P, Bhosle V, Varma DR, Gobeil Jr F, Beauséjour C, Boileau C, Klein W, Hollenberg M, Ribeiro-da-Silva A, Andelfinger G, Chemtob S. (2014). Subcellular localization of coagulation factor II receptor-like 1 in neurons governs angiogenesis. Nature Medicine, 20(10), 1165-1173. (Article publié).
  • Brouillette M, Doré M, Hébert C, Spooner MF, Marchand S, Côté J*, Gobeil F, Rivest M, Lafrance M, Talbot B, Moutquin JM. (2013). A new biolistic intradermal injector. Shock Waves, (DOI 10.1007/s00193-, 1-13. (Article publié).
  • Côté J*, Savard M*, Neugebauer W, Fortin D, Lepage M , Gobeil F. (2013). Dual kinin B1 and B2 receptor activation provides enhanced blood-brain barrier permeability and anticancer drug delivery into brain tumors. Cancer Biology & Therapy, 14(9), 1-6. (Article publié).
  • Brochu I , Houde M , Desbiens L , Simard E , Gobeil F , Semaan W , Bkaily G , D'Orléans-Juste P. (2013). High salt induced hypertension in B2 knockout mice is corrected by the ETA antagonist, A127722. British journal of pharmacology, 170, 266-277. (Article publié).
  • Potier L, Waeckel L, Vincent MP, Chollet C, Gobeil F, Marre M, Richer C, Roussel R, Alhenc-Gelas F, Bouby N. (2013). Kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes (Highlighted paper). J Pharm Exp Ther, 346, 23-30.
  • Rochon K , Proteau-Gagné A , Bourassa P , Nadon JF , Côté J*, Bournival V , Gobeil F , Guérin B , Dory YL , Gendron L. (2013). Preparation and Evaluation at the Delta Opioid Receptor of a Series of Linear Leu-Enkephalin Analogues Obtained by Systematic Replacement of the Amides. ACS Chem Neurosci, 4, 1204-1216. (Article publié).
  • Regoli D , Plante GE , Gobeil F. (2012). Impact of kinins in the treatment of cardiovascular diseases. Pharmacology & Therapeutics, 135(1), 94-111.
  • Côté J , Bovenzi V , Savard M , Dubuc C , Fortier A , Neugebauer W , Tremblay L , Müller-Esterl W , Tsanaclis AM , Lepage M , Fortin D , Gobeil F. (2012). Induction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat model. PloS one, 7(5), 1-17. (Article publié).
  • Bovenzi V*, Savard M*, Morin J*, Cuerrier CM*, Grandbois M , Gobeil F. (2010). Bradykinin protects against brain microvascular endothelial cell death induced by pathophysiological stimuli. Journal of cellular physiology, 222(1), 168-176. (Article publié).
  • Provost C , Choufani F , Avedanian L , Bkaily G , Gobeil F , Jacques D. (2010). Nitric oxide and reactive oxygen species in the nucleus revisited. Canadian journal of physiology and pharmacology, 88(3), 296-304.
  • Côté J , Savard M , Bovenzi V , Dubuc C , Tremblay L , Tsanaclis AM , Fortin D , Lepage M , Gobeil F. (2010). Selective tumor blood-brain barrier opening with the kinin B2 receptor agonist [Phe(8)psi(CH(2)NH)Arg(9)]-BK in a F98 glioma rat model: an MRI study. Neuropeptides, 44(2), 177-185.
  • Re M , Pampillo M , Savard M*, Dubuc C*, McArdle CA , Millar RP , Conn PM , *Gobeil F , Bhattacharya M , Babwah AV. (2010). The human gonadotropin releasing hormone type I receptor is a functional intracellular GPCR expressed on the nuclear membrane. PloS one, 5(7), 1-14. (Article publié).
  • Côté J , Savard M , Bovenzi V , Bélanger S , Morin J , Neugebauer W , Larouche A , Dubuc C , *Gobeil F. (2009). Novel kinin B1 receptor agonists with improved pharmacological profiles. Peptides, 30(4),
  • Bossi F , Fischetti F , Regoli D , Durigutto P , Frossi B , Gobeil F , Ghebrehiwet B , Peerschke EI , Cicardi M , Tedesco F. (2009). Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. The Journal of allergy and clinical immunology, 124(6), 1303-1310. (Article publié).
  • Cuerrier CM , Benoit M , Guillemette G , Gobeil F , Grandbois M. (2009). Real-time monitoring of angiotensin II-induced contractile response and cytoskeleton remodeling in individual cells by atomic force microscopy. Pflügers Archiv : European journal of physiology, 457(6),
  • Bélanger S , Bovenzi V , Côté J , Neugebauer W , Amblard M , Martinez J , Lammek B , Savard M , *Gobeil F. (2009). Structure-activity relationships of novel peptide agonists of the human bradykinin B2 receptor. Peptides, 30(4),
  • Rihakova L , Quiniou C , Hamdan FF , Kaul R , Brault S , Hou X , Lahaie I , Sapieha P , Hamel D , Shao Z , Gobeil F , Hardy P , Joyal JS , Nedev H , Duhamel F , Beauregard K , Heveker N , Saragovi HU , Guillon G , Bouvier M , Lubell WD , Chemtob S. (2009). VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist. American journal of physiology. Regulatory, integrative and comparative physiology, 297(4),

Articles de conférence

  • Placet M, McManus S, Arguin G, Savard M, Gendron FP, Gobeil F Jr. (2019). Could B1R be an actor in tumorigenicity of U87MG cells via EMT-like mechanism?. First international conference on Chronic Inflammation, Immunity and Cancer. (Article publié).
  • Ardilouze JL, Gobeil F jr, Ménard J, Bovan D, Messier V, Savard M, Baillargeon JP, Rabasa-Lhoret R. (2019). Insulin pump catheters can be worn much more than the recommended 3 days. American Diabetes Association's 79th scientific metting. Diabetes 68 (Suppl. 1): 1048-P. (Article publié).
  • Ardilouze JL, Gobeil F jr, Ménard J, Bovan D, Messier V, Savard M, Baillargeon JP, Rabasa-Lhoret R. (2019). Towards prolongation of insulin pump catheters wearingtime using a mixture of insulin and a non-steroidal anti-inflammatory drug. American Diabetes Association's 79th scientific metting. Diabetes 68 (Suppl. 1) 1049-P. (Article publié).
  • Gobeil F. (2017). Improving CNS delivery of oncotherapeutics with novel kinin-based BBB permeabilizers. Annual meeting (7th edition) of Drug Research Quebec Network (RQRM). (Article accepté).
  • Gobeil F & Regoli D. (2016). Criteria for the choice of ACE-inhibitors as drugs in the treatment of cardiovascular diseases. Annual Meeting of the North American Section of the International Academy of Cardiovascular Sciences. Program–IACS meeting, p. 66. (Article publié).
  • Gagnon M, Savard M, Roucou X, Gobeil F. (2016). Potentiation of bradykinin B2R activity by heterologous expression of a newly-identified protein coded by an alternative ORF of the B2R mRNA. Annual Meeting of the North American Section of the International Academy of Cardiovascular Sciences. Program–IACS meeting, p. 49. (Margaret P. Moffat Award). (Article publié).
  • Regoli D & Gobeil F. (2016). Rational bases of modern therapies for cardiovascular diseases. Annual Meeting of the North American Section of the International Academy of Cardiovascular Sciences. Program–IACS meeting, p.73-74. (Article publié).
  • Gobeil jr F, Savard M, Dubuc C, Côté J, Dumulon-Perreault V, Paquette M, Croteau E, Ait-Mohand S, Guérin B. (2015). Novel Kinin-Based Analogues as Potential BBB-Penetration Enhancers for Delivery of Chemotherapy and as New Theranostic Agents for Imaging and Treatment of Malignant Brain Cancer. Kinin 2015 (Brazil). (Article publié).
  • Gagnon M, Motard J, Jacques JF, Gobeil F, Roucou X. (2015). The multicoding potential of GPCR genes. The 15th Annual PROTEO Symposium. (Article publié).
  • Savard M, Côté J, Tremblay L, Neugebauer W, Regoli D, Gariépy S, Broadhurst M, Gobeil jr F. (2015). Toxicokinetics of a kinin B1 receptor peptidomimetic agonist produced with different counter-ions. Kinin 2015 (Brazil). (Article publié).
  • Desposito D, Potier L, Chollet C, Gobeil Jr F, Roussel R, Bouby N, Alhenc-Gelas F, Waeckel L. (2014). Selective pharmacological kinin receptors activation restores postischemic neovascularisation and hindlimb perfusion in diabetic mice. American Heart Association Council on High Blood Pressure Research 2014 scientific meeting. (Article soumis).
  • Coté J, Savard M, Neugebauer W, Fortin D, Lepage M, Gobeil F Jr (CIHR-ICR travel award). (2013). Dual kinin B1 and B2 receptor activation provides enhanced blood-brain barrier permeability and anticancer drug delivery into brain tumors. The Canadian Cancer Research Conference. Abstract book, p, 316. (Article publié).
  • Gagnon-Auger M, Gobeil Jr F, Ardilouze JL. (2013). Exploration des défaillances du flot sanguin dans le tissu adipeux sous-cutané chez des sujets obèses et insulinorésistants. 55e réunion annuelle, Club de recherche clinique du Québec. (Article accepté).
  • Côté J, Lepage M, Gobeil F jr. (2013). La co-activation des récepteurs B1 et B2 des kinines améliore la biodisponibilité intracérébrale et l’efficacité de la chimiothérapie des tumeurs cérébrales (modèle F98). 55e réunion annuelle, Club de recherche clinique du Québec. (Article accepté).
  • Gobeil jr, F. (2013). New class of drugs for the treatment of pain and inflammation associated to diabetes. 1er Colloque Réseau Québecois de Recherche sur les medicaments-Industrie. (Article publié).
  • Fernand Gobeil jr. (2013). New strategy for reversible, non-invasive modulation of the blood-brain barrier to potentiate CNS drug delivery. 1er colloque Réseau Québecois de Recherche sur les medicaments-Industrie. (Article publié).
  • Dubuc C, Savard M, Bovenzi V, Gobeil F jr. (2013). Étude de l'expression des récepteurs B1 des kinines chez différentes lignées de cancer du sein humain. 55e réunion annuelle, Club de recherche clinique du Québec. (Article accepté).
  • Gobeil F jr. (2012). Agonistes synthétiques des kinines: Optimiser la livraison et l’efficacité des chimiothérapies des tumeurs cérébrales. Réseau Québecois de Recherche sur les medicaments. (Article publié).
  • Dubuc C, Savard M, Bovenzi V, Neugebauer W, *Gobeil F jr. (2012). Arrêt de la proliferation et induction de l’apoptose des cellules humaines de cancer du sein par des antagonistes perméants des récepteurs B2 de la bradykinine. 54e réunion annuelle, Club de recherche clinique du Québec. (Article publié).
  • Côté J, Tremblay L, Fortin D, *Gobeil F Jr, Lepage M. (2012). DCE-MRI and ICP-MS evaluation of biodistribution of contrast agents and chemotherapeutic agents to gliomas with a new pharmacological approach in F98 glioma cells implanted Fischer rats. The International Society for Magnetic Resonance in Medicine (ISMRM) 2012, Australia. (Article publié).
  • Potier L, Waeckel L, Vincent MP, Chollet C, Marre M, Gobeil F jr, Richer C, Roussel R, Alhenc-Gelas F, Bouby N. (2012). Effect of (B1 and B2) bradykinin receptor agonists on cardiac ischemia reperfusion injury in the mouse. Kinin 2012, Paris. (Article publié).
  • Savard M, Labonté J, Tremblay A, Dubuc C, Neugebauer W, Plante GE, D’Orléans-Juste P, *Gobeil F jr. (2012). Further pharmacological evaluation of a novel peptide bradykinin B2 receptor agonist. Kinin 2012, Paris. (Article publié).
  • Dubuc C, Bovenzi V, Savard M, Neugebauer W, Gobeil Jr F. (2012). Induction of growth arrest and apoptosis of human breast cancer cells with cell-penetrating kinin B2 receptor antagonists. Kinin 2012. (Article publié).
  • Côté J, Bovenzi V, Savard M, Dubuc C, Lepage M, Fortin D, *Gobeil F jr. (2012). Induction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat model. Kinin 2012, Paris. (Article publié).
  • Gobeil F jr. (2012). Potential use of synthetic kinin B1 receptor agonists as permeability enhancers for improving drug delivery to malignant brain tumours. Kinin 2012, Paris. (Article publié).
  • Roussel R, Waeckel L, Potier L, Gobeil F, Richer-Giudicelli C, Bouby N, Alhenc-Gelas F. (2012). Protective role of kallikrein-kinins, from gene inactivation to pharmacological agonism. Kinin 2012, Paris. (Article publié).
  • Savard M, Neugebauer W, Côté J, Dubuc C, Bovenzi V, *Gobeil F. (2011). Pharmacological evaluation of novel fluorescently-labeled analogs of Icatibant. 22nd American Peptide Symposium. Biopolymers Peptide Scie. (Article publié).
  • *Gobeil F jr, Côté J, Savard M, Bovenzi V, Dubuc C, Lepage M, Fortin D. (2011). Potential use of synthetic kinin B1 receptor agonists as permeability enhancers for improving drug delivery to malignant brain tumours. Canadian Society of Pharmacology & Therapeutic (CSPT) annual conference. (Article publié).

Propriétés intellectuelles

Brevets

  • (2012). Kinin B1 receptor peptide agonists and uses thereof. EP1937710. France. (Délivré).
  • (2012). Kinin B1 receptor peptide agonists and uses thereof. EP1937710B1. Allemagne. (Délivré).
  • (2012). Kinin B1 receptor peptide agonists and uses thereof. EP1937710B1. Royaume-Uni. (Délivré).
  • (2012). Novel selective bradykinin B1 peptidic receptor antagonists and uses thereof. CA 2,423,876. Canada. (Délivré).
  • (2011). Kinin B1 receptor peptide agonists and uses thereof (licensed products). US 11/916,136. États-Unis. (Délivré).
  • (2008). B1-Bradykinin receptor antagonists and use thereof. MX 254796. Mexique. (Délivré).
  • (2007). Novel selective bradykinin B1 peptidic receptor antagonists and uses thereof (licensed products). US 7,211,566. États-Unis. (Délivré).
  • (2006). B1 Bradykinin receptor antagonists and use thereof. US 7,041,785. États-Unis. (Délivré).
  • A pharmaceutical preparation for improving absorption and post-prandial hypoglycemic action of insulin (patent sold to a major pharmaceutical firm undisclosed for confidentuality reasons). USPTO, provisory patent application # 62/197,833. États-Unis. (En instance).
  • A pharmaceutical preparation for improving infusion sets longevity of continous subcutanous insulin infusion systems. PCT/CA2018/0510892. États-Unis. (En instance).
  • Methods and pharmaceutical compositions for prevention or treatment of ischemia related organ damage. EP12305349.8. France. (En instance).
  • Novel kinin-based theranostic probes for solid cancers and uses thereof (licensed products). USPTO, provisory patent application # 62/184,268. États-Unis. (En instance).
  • Peptidic and peptidoid bradykinin B1 receptor antagonists and uses thereof. US 11/660,436. États-Unis. (Retiré).
  • Peptidic and peptidoid bradykinin B1 receptor antagonists and uses thereof. CA 2,600,906. Canada. (Retiré).
  • Peptidic and peptidoid bradykinin B1 receptor antagonists and uses thereof. EU 57772234,5. France. (Retiré).
  • Use of an B2 receptor agonist and of a pharmaceutical composition. BR 10 2020 020077 1. Brésil. (En instance).

Licences

  • 7 out-licensing of compounds to biotechnology firms. (Licence obtenue).

Autres contributions

Cours enseignés

  • Nouveau cursus en médecine (APÉ et APP): MSP112, MSP114, MSP115, MSP131 et MSP305. (2017-05-01). Université de Sherbrooke. Canada.
  • Autacoïdes et hormones. PHR 702. (2012-03-03). Université de Sherbrooke. Canada.
  • Pharmacologie générale. PHR 504 (session été). (2011-06-02). Université de Sherbrooke. Canada.
  • Membre du comité d’orientation du programme de baccalauréat en pharmacologie. (2011-01-03). Université de Sherbrooke. Canada.
  • Membre du comité d’habilitation pour le programme de pharmacologie. (2006-01-03). Université de Sherbrooke. Canada.
  • Études médicales prédoctorales. Biomed 1. (2004-09-07 à 2016-10-01). Université de Sherbrooke. Canada.
  • Membre du groupe de travail pour l’amélioration de la formation doctorale (présidé par Pr Jean Nicholas). (2004-01-05). Université de Sherbrooke. Canada.
  • Pharmacologie générale. PHR504 (session hiver). (2003-01-08). Université de Sherbrooke. Canada.
  • Membre du comité d’éthique de l’expérimentation animale (FMSS). (2003-01-07). Université de Sherbrooke. Canada.

Gestion d'évènements

  • International scientific advisory board member. Kinin 2015 Brazil. (Conférence).
  • Organisator. Organisation committee of the XIII Annual Meeting of the North East Smooth Muscle Society. (Conférence).

Présentations

  • (2017). Improving CNS delivery of oncotherapeutics with novel kinin-based BBB permeabilizers. Annual meeting (7th edition) of Drug Research Quebec Network (RQRM). Canada.
  • (2016). Criteria for the choice of ACE-inhibitors as drugs in the treatment of cardiovascular diseases. International Academy of Cardiovascular Sciences (IACS) congress. Canada.
  • (2015). Novel kinin-based analogues as potential BBB-penetration enhancers for delivery of chemotherapy and as new theranostic agents for imaging and treatment of malignant brain cancers. Kinin 2015 (Brazil). Sau Paolo, Brésil.
  • (2013). New class of drugs for the treatment of pain and inflammation associated to diabetes. colloque RQRM-Industrie (Neomed). Montréal, Canada.
  • (2013). New strategy for reversible, non-invasive modulation of the blood-brain barrier to potentiate CNS drug delivery. Colloque RQRM-Industrie (Neomed). Montreal, Canada.
  • Gobeil jr, F. (2012). Agonistes synthétiques des kinines: Optimiser la livraison et l’efficacité des chimiothérapies des tumeurs cérébrales. Québec Network on Drug Research (RQRM) 2nd meeting (September 2012). Montreal, Canada.
  • (2012). Potential use of kinin B1 receptor agonists as permeability enhancers for improving drug delivery to malignant brain tumours. Kinin 2012 (Paris, France). Paris, France.
  • Michel C & Gobeil Jr F. (2011). Novel kinin B1R peptide agonists to potentiate CNS drug delivery. TechConnect Summit. Boston, États-Unis.
  • (2010). Agonistes synthétiques des récepteurs B1 des kinines comme peptides adjuvants pour accroître l’acheminement et l’efficacité d’agents anticancéreux dans la thérapie des tumeurs cérébrales. PHARE 2010. Sherbrooke, Canada.